1. [CASE 1 — QUESTION 1] A 38-year-old woman with HAE type I presents to the emergency department with a 90-minute history of progressive throat tightness, dysphonia, and difficulty swallowing. She carries a diagnosis of HAE type I confirmed by low C1-INH level and function, with low C4. She has experienced prior abdominal and cutaneous attacks but this is her first laryngeal attack. Her medications include no long-term HAE prophylaxis. She is visibly anxious, her voice is muffled, and she has mild stridor. The emergency physician confirms airway equipment is at bedside and decides to administer icatibant 30 mg subcutaneously. Which of the following best describes the pharmacological mechanism by which icatibant will interrupt this laryngeal HAE attack, and why subcutaneous administration is appropriate for this agent?

• A) Icatibant inhibits plasma kallikrein at the site of contact system activation in the laryngeal submucosa, preventing further cleavage of HMWK and halting new bradykinin generation; subcutaneous administration is appropriate because the subcutaneous depot provides slow-release kallikrein inhibition that outlasts the duration of the acute attack stimulus.
• B) Icatibant is a competitive antagonist at the bradykinin B2 receptor and blocks the ability of bradykinin already accumulated in laryngeal submucosal tissues to drive vascular permeability and edema; subcutaneous administration delivers the drug into the interstitial compartment where it can distribute to tissue B2 receptors, achieving peak plasma concentrations within approximately 45 to 75 minutes with a clinical duration of effect of 6 to 8 hours despite a short plasma half-life of 1 to 2 hours.
• C) Icatibant activates bradykinin B1 receptors, which mediate vasoconstriction at laryngeal mucosal capillaries through a Gi-coupled signaling pathway that opposes the vasodilatory effects of B2 receptor activation by bradykinin; subcutaneous administration allows slow absorption that prevents systemic B1-mediated vasoconstriction from producing laryngeal ischemia.
• D) Icatibant replaces deficient C1 inhibitor at the site of contact system activation, directly inhibiting plasma kallikrein and factor XIIa through a covalent serpin mechanism; subcutaneous administration is preferred over intravenous delivery for laryngeal attacks because the subcutaneous route produces higher peak tissue concentrations in the perilaryngeal compartment than IV administration.
• E) Icatibant competitively inhibits ACE (kininase II) at mucosal endothelial surfaces, preventing the degradation of substance P and bradykinin simultaneously; subcutaneous administration is appropriate because the gastrointestinal absorption of icatibant is unreliable in laryngeal HAE attacks where patients frequently have concurrent esophageal edema that impairs oral drug absorption.

2. [CASE 1 — QUESTION 2] Continuing with the same patient. Icatibant 30 mg was administered subcutaneously 2 hours ago. The patient's stridor has partially improved and her voice is clearer, but she still has mild throat tightness and the emergency physician judges that the attack is incompletely resolved. The patient asks whether a second injection can be given. Which of the following correctly describes the approved repeat-dosing protocol for icatibant in an incompletely resolved HAE attack?

• A) A second dose of icatibant cannot be administered within 24 hours of the first because the B2 receptor undergoes pharmacological desensitization within 2 to 4 hours of competitive antagonist exposure; administering a second dose before receptor resensitization is complete will have no pharmacodynamic effect and wastes medication that the patient will need if the attack recurs within the next 24 hours.
• B) A second dose of icatibant 30 mg may be administered if symptoms recur or are incompletely controlled, but only after the patient has been observed for a minimum of 4 hours in the emergency department for anaphylaxis monitoring; because icatibant is a synthetic peptide derived from a modified bradykinin sequence, repeat dosing carries a cumulative anaphylaxis risk similar to ecallantide that requires supervised administration after the first dose.
• C) A second dose of icatibant is not indicated for incomplete attack resolution because partial improvement within 2 hours is the expected clinical trajectory of a treated laryngeal attack; the approved protocol requires waiting a full 8 hours before assessing treatment failure, at which point the clinician should switch to ecallantide rather than administering additional icatibant.
• D) A second dose of icatibant 30 mg may be given if symptoms persist after the first dose, but must be administered intravenously rather than subcutaneously for the repeat dose; the intravenous route achieves faster peak concentrations and is specifically approved for the second dose of icatibant when the subcutaneous first dose has produced only partial response.
• E) A second dose of icatibant 30 mg may be administered if symptoms recur or are incompletely controlled after the first dose, provided at least 6 hours have elapsed since the first injection; a third dose is available if symptoms persist after the second, also separated by at least 6 hours, for a maximum of three doses per attack episode; icatibant does not require supervised administration for repeat doses as it carries no anaphylaxis risk.

3. [CASE 1 — QUESTION 3] Continuing with the same patient. The attack has fully resolved after a second icatibant dose. During discharge counseling, the patient asks why she was not given ecallantide instead, since her friend with HAE uses ecallantide and says it works faster by stopping bradykinin production rather than blocking its receptor. The physician explains the key pharmacological and safety distinction that makes ecallantide unsuitable for home self-administration. Which of the following correctly identifies this distinction?

• A) Ecallantide cannot be self-administered at home because it requires reconstitution from lyophilized powder using a sterile diluent and a two-syringe mixing technique that cannot be reliably performed by patients without pharmacy training; icatibant is supplied as a ready-to-inject solution in a prefilled syringe that requires no preparation.
• B) Ecallantide cannot be self-administered at home because it has a narrow therapeutic window requiring real-time plasma kallikrein activity monitoring to guide dosing; without laboratory confirmation that kallikrein inhibition is adequate, there is a risk of either subtherapeutic dosing (attack progression) or supratherapeutic dosing (excessive contact system suppression impairing normal coagulation).
• C) Ecallantide carries a risk of anaphylaxis in approximately 3.9% of patients — attributed to anti-ecallantide antibody development or direct mast cell activation by the recombinant protein — and therefore must be administered in a healthcare setting equipped to manage anaphylaxis; icatibant does not carry this anaphylaxis risk and is approved for patient self-administration at home following appropriate training.
• D) Ecallantide cannot be self-administered at home because its mechanism of upstream kallikrein inhibition requires co-administration of fresh frozen plasma to provide sufficient HMWK substrate for the drug to demonstrate its competitive inhibition; without the FFP co-administration that can only be performed in a healthcare setting, ecallantide's efficacy is significantly reduced.
• E) Ecallantide is restricted to healthcare settings because the FDA requires electrocardiographic monitoring during and for 4 hours after ecallantide administration due to its dose-dependent QT-prolonging effect; icatibant has no cardiac safety monitoring requirement because its B2 receptor antagonism does not affect cardiac ion channel conductance.

4. [CASE 1 — QUESTION 4] Continuing with the same patient. The HAE specialist sees the patient before discharge and notes that this was her first laryngeal attack and she has been having increasing attack frequency over the past year. The specialist recommends initiating long-term prophylaxis and discusses the modern options. Which of the following correctly characterizes the appropriate first-line long-term prophylactic approach for this patient and the rationale for the recommendation?

• A) Long-term prophylaxis with either lanadelumab (subcutaneous anti-kallikrein monoclonal antibody, 300 mg every 2 weeks) or subcutaneous HAEGARDA (plasma-derived C1-INH, 60 IU/kg twice weekly) is appropriate as a first-line choice; both are superior to danazol in efficacy and safety for long-term use, and the choice between them is guided by patient preference, injection frequency tolerance, and access; danazol should be reserved for patients who fail or cannot access biologic options due to its hepatotoxic, virilizing, and metabolic adverse effects.
• B) Long-term prophylaxis should begin with danazol at the lowest effective dose (100 to 200 mg daily) as first-line because its 40-year track record provides the most robust long-term safety data of any HAE prophylactic agent; modern biologics such as lanadelumab should be reserved for patients who develop danazol-related adverse effects or who have disease refractory to androgen therapy.
• C) Long-term prophylaxis should begin with intravenous Cinryze (pdC1-INH, 1000 IU every 3 to 4 days) administered by the patient via self-placed peripheral IV at home; this approach provides the most physiologically complete correction of the HAE defect and should precede consideration of targeted kallikrein inhibitors such as lanadelumab for all patients with documented laryngeal attacks.
• D) Long-term prophylaxis is not currently indicated because this was the patient's first laryngeal attack; current HAE guidelines require at least three laryngeal attacks within 12 months before initiating prophylaxis to avoid unnecessary long-term biologic exposure in patients who may have isolated severe attacks; the patient should be educated on aggressive rescue therapy and return to clinic after further attacks.
• E) Long-term prophylaxis with tranexamic acid 1 to 1.5 g orally three times daily is the appropriate first-line choice because tranexamic acid's antifibrinolytic mechanism suppresses plasmin-mediated contact system activation without introducing immunogenic biologic agents; modern biologics should be reserved for tranexamic acid failures because their immunogenicity profile in young women of reproductive age has not been fully characterized in long-term registry data.

5. [CASE 2 — QUESTION 1] A 26-year-old woman with HAE type I (confirmed low C1-INH level and low C4) is 20 weeks pregnant with her first pregnancy. She presents to the obstetric unit with severe abdominal cramping and diffuse abdominal distension that her HAE specialist confirms is an acute HAE attack. Prior to pregnancy she managed attacks with icatibant. The obstetric team asks the HAE specialist which acute treatment is safest and most appropriate in the second trimester. Which of the following most accurately identifies the preferred acute treatment for HAE attacks during pregnancy and the pharmacological basis for this preference?

• A) Icatibant remains the preferred acute HAE treatment during pregnancy because its synthetic peptide structure undergoes hydrolysis by plasma peptidases before reaching significant placental concentrations, and the non-natural amino acid residues that confer its protease resistance in plasma are specifically cleaved by placental peptidase isoforms not present in systemic circulation, providing fetal protection.
• B) Ecallantide is the preferred acute treatment in pregnancy because preventing bradykinin generation (upstream kallikrein inhibition) is more effective than blocking bradykinin at its receptor; ecallantide prevents fetal B2 receptor exposure to circulating maternal bradykinin, which could theoretically impair fetal vascular development through its normal developmental signaling function.
• C) Fresh frozen plasma is the preferred acute treatment during pregnancy because it simultaneously provides C1-INH, fibrinogen for obstetric hemorrhage prevention, and immunoglobulins for maternal-fetal immune transfer; no other single pharmacological intervention provides this combination of obstetric and HAE benefits.
• D) Plasma-derived C1 inhibitor concentrate is the first-line treatment for acute HAE attacks during pregnancy and is specifically endorsed by current international HAE guidelines for this indication; it replaces the deficient serpin without introducing synthetic pharmacological agents across the placental barrier and has a documented safety record in pregnant HAE patients from registry data and clinical experience.
• E) No pharmacological treatment should be administered for this acute abdominal attack during the second trimester; HAE abdominal attacks are self-limiting within 24 to 72 hours, and the risks of any HAE pharmacotherapy to fetal organogenesis during the second trimester outweigh the maternal benefit; supportive care with IV hydration and pain management is the recommended standard.

6. [CASE 2 — QUESTION 2] Continuing with the same patient. The HAE specialist orders Berinert (plasma-derived C1-INH concentrate) for the acute abdominal attack. The obstetric nurse asks the specialist to confirm the correct dose and route, and why weight-based intravenous dosing is used rather than a fixed subcutaneous dose. Which of the following correctly states the approved dosing of Berinert for acute attack treatment and explains the rationale for the IV route over subcutaneous delivery in this acute setting?

• A) Berinert is administered intravenously at 20 IU/kg body weight; the weight-based dose ensures that circulating C1-INH levels are restored into or above the normal physiological range regardless of the patient's baseline C1-INH deficit, and the intravenous route is required because it achieves rapid distribution of the protein into the plasma compartment where it can immediately inhibit active plasma kallikrein, producing onset of symptom relief within 30 to 60 minutes — a rate of delivery that subcutaneous absorption cannot match in an acute attack.
• B) Berinert is administered intravenously at a fixed dose of 1000 IU regardless of body weight; the fixed dose was established in clinical trials as the minimum needed to raise plasma C1-INH activity to the normal range in 95% of adult patients; weight-based dosing is used only in pediatric patients under 12 years of age where body surface area variability makes fixed dosing unreliable.
• C) Berinert is administered subcutaneously at 60 IU/kg twice weekly; while intravenous administration produces faster onset, the subcutaneous route is preferred in pregnancy because it avoids IV cannulation and reduces the risk of maternal venous thromboembolism from repeated IV access; the twice-weekly schedule ensures continuous therapeutic C1-INH levels throughout the obstetric admission.
• D) Berinert is administered intravenously at 50 IU/kg to a maximum of 4200 IU per dose; the higher weight-based dose compensates for the increased plasma volume of pregnancy, which dilutes the administered C1-INH and requires a proportionally larger dose to achieve the same plasma concentration as in non-pregnant adults.
• E) Berinert is administered by slow intravenous infusion at 1 IU/kg/hour titrated to clinical response; the infusion titration approach is used in pregnancy to minimize peak C1-INH concentrations that could theoretically inhibit complement pathway components needed for normal placental implantation and maternal immune tolerance of the fetal allograft.

7. [CASE 2 — QUESTION 3] Continuing with the same patient. The attack resolves with Berinert. The patient reports that before becoming pregnant she had been taking danazol 200 mg daily for HAE prophylaxis, which she stopped when she learned she was pregnant. Her obstetrician asks the HAE specialist to confirm whether stopping danazol was the correct decision and what the teratogenic risk would have been had she continued. Which of the following correctly characterizes danazol's reproductive safety profile and explains why discontinuation before conception is mandatory?

• A) Stopping danazol was the correct decision, but it was necessary only during the first trimester when fetal organogenesis is ongoing; danazol may be restarted safely at low doses (100 mg daily) in the second and third trimesters because androgen receptor expression in fetal tissues decreases after 12 weeks of gestation, substantially reducing virilization risk during the later pregnancy period.
• B) Stopping danazol was appropriate but not strictly necessary; danazol's androgenic effects are mediated through the maternal androgen receptor in hepatocytes, and the hepatic first-pass metabolism of danazol produces inactive metabolites that do not cross the placental barrier in androgenically active form; the primary reason for stopping danazol in pregnancy is maternal hepatotoxicity risk rather than fetal teratogenicity.
• C) Stopping danazol before conception was mandatory because danazol is absolutely contraindicated throughout pregnancy; it crosses the placental barrier and exerts androgenic effects on fetal tissues, and female fetuses exposed to danazol in utero have developed virilization including clitoral hypertrophy, labioscrotal fusion, and other androgenic effects on external genitalia — a risk that applies across all trimesters and cannot be mitigated by dose reduction.
• D) Stopping danazol was correct, but the teratogenic risk is limited to cardiac septal defects from androgen receptor-mediated inhibition of cardiac neural crest cell migration during weeks 6 to 10 of gestation; since this patient is 20 weeks pregnant and the cardiac developmental window has closed, she could theoretically resume low-dose danazol for the remainder of pregnancy if C1-INH concentrate becomes unavailable.
• E) Stopping danazol was unnecessary because the fetal liver does not express androgen receptors until the third trimester; danazol's androgenic effects on fetal development only become clinically relevant after 28 weeks of gestation, and the patient's second-trimester presentation means her fetus has had no meaningful androgenic exposure from the danazol she took before stopping at conception.

8. [CASE 2 — QUESTION 4] Continuing with the same patient. The HAE specialist now plans for the remainder of the pregnancy and the postpartum period. The patient had three HAE attacks in the second trimester alone and asks whether she needs ongoing prophylaxis through delivery. The specialist explains that HAE attack frequency typically worsens in the second and third trimesters as estrogen levels rise, and discusses which prophylactic agent is appropriate during this period. Which of the following correctly identifies the recommended prophylactic approach for the remainder of this patient's pregnancy and the pharmacological reason estrogen elevation worsens HAE?

• A) Lanadelumab 300 mg subcutaneously every 2 weeks should be initiated immediately as the preferred prophylactic agent for the remainder of pregnancy; its monoclonal antibody structure prevents placental transfer in clinically significant amounts, and its every-2-week dosing interval reduces the frequency of injections compared to subcutaneous pdC1-INH while providing superior kallikrein inhibition during the high-estrogen state of late pregnancy.
• B) Tranexamic acid 1.5 g orally three times daily is the preferred prophylactic agent during pregnancy because its antifibrinolytic mechanism suppresses plasmin-mediated factor XII activation without introducing any kallikrein-kinin system pharmacology; its oral route avoids injection site complications and its safety in pregnancy is established from its use in obstetric hemorrhage prevention.
• C) No pharmacological prophylaxis is recommended during pregnancy because the risk of any HAE agent to the fetus outweighs the benefit of attack prevention; the patient should be managed with on-demand IV Berinert at every attack, accepting the increased attack frequency as an unavoidable consequence of the pregnancy-associated estrogen elevation.
• D) Oral danazol at a reduced dose of 50 mg daily can be safely used for HAE prophylaxis during the second and third trimesters; at doses below 100 mg daily, danazol's androgenic potency is insufficient to produce fetal virilization, and the hepatic C1-INH upregulation it provides is the most effective prophylactic mechanism available during the estrogen-driven contact system activation of late pregnancy.
• E) Intravenous or subcutaneous plasma-derived C1-INH concentrate is the guideline-endorsed prophylactic agent for HAE during pregnancy; estrogen worsens HAE by upregulating hepatic HMWK gene expression (increasing bradykinin precursor substrate) while simultaneously downregulating hepatic C1-INH synthesis, creating a progressively worsening substrate-to-inhibitor imbalance that attacks worsen through the third trimester; C1-INH concentrate replacement directly addresses this deficit safely throughout pregnancy.

9. [CASE 3 — QUESTION 1] A 72-year-old man with HFrEF (ejection fraction 28%) has been stable on enalapril 10 mg twice daily, carvedilol, furosemide, and spironolactone for 4 years. His cardiologist wishes to transition him to sacubitril-valsartan 49/51 mg twice daily. The cardiologist instructs the patient to take his last enalapril dose on a Monday morning and start sacubitril-valsartan on Wednesday morning. Which of the following correctly explains the pharmacokinetic rationale for the 36-hour washout between the last enalapril dose and the first sacubitril-valsartan dose?

• A) The 36-hour washout is based on the half-life of enalaprilat — the active ACE-inhibiting metabolite formed from enalapril by hepatic esterases — which is approximately 11 hours; 36 hours represents approximately 3.3 half-lives of enalaprilat, reducing residual ACE inhibitory activity to pharmacodynamically insignificant levels before sacubitril's neprilysin inhibition is added; without this washout, simultaneous ACE and neprilysin inhibition would block two of the three major bradykinin-clearing pathways simultaneously, producing synergistic bradykinin accumulation and substantially elevated angioedema risk.
• B) The 36-hour washout is based on the half-life of valsartan in sacubitril-valsartan (approximately 9 to 13 hours); because valsartan and enalapril both modulate renin-angiotensin system activity, their simultaneous presence produces additive AT1 receptor blockade and ACE inhibition that causes dangerous hypotension from combined RAAS suppression; 36 hours allows valsartan from any prior residual dose to clear before enalapril is stopped.
• C) The 36-hour washout is required because enalapril induces CYP3A4 over weeks of chronic therapy, and this enzyme induction increases the rate of sacubitril's conversion to LBQ657 to supratherapeutic levels; 36 hours after stopping enalapril, CYP3A4 activity begins returning toward baseline, reducing the risk of excessive neprilysin inhibition from accelerated prodrug activation.
• D) The 36-hour washout is based on the time required for bradykinin B2 receptors at vascular endothelial surfaces to return to their baseline expression level after the sustained upregulation caused by chronic ACE inhibitor therapy; without receptor normalization, sacubitril-valsartan would act on a sensitized B2 receptor pool that produces angioedema at bradykinin concentrations too low to cause symptoms in a drug-naive patient.
• E) The 36-hour washout is a regulatory rather than pharmacological requirement, established by the FDA as a conservative safety interval based on preclinical animal data showing myocardial toxicity when enalapril and sacubitril were co-administered in rodents; in clinical practice, cardiologists commonly reduce the washout to 24 hours without adverse consequences because the pharmacokinetic interaction is clinically insignificant at therapeutic doses.

10. [CASE 3 — QUESTION 2] Continuing with the same patient. The 36-hour washout was observed correctly. Two weeks after starting sacubitril-valsartan, the patient's wife calls the cardiology office reporting that her husband has progressive lip and tongue swelling that began 4 hours ago. He has no skin rash, no itching, and no shortness of breath. He is alert and his voice is normal. He has no prior history of angioedema. Which of the following most accurately identifies the mechanism of this adverse event and the pharmacological reason antihistamines and corticosteroids will not provide meaningful relief?

• A) This presentation represents an allergic reaction to valsartan, the ARB component of sacubitril-valsartan; ARB-class angioedema is mediated by cross-reactive IgE antibodies generated against enalapril's enalaprilat metabolite during prior ACEI therapy; antihistamines will be partially effective because IgE-mediated angioedema has a mixed histamine and complement-mediated permeability component.
• B) This presentation represents carvedilol-induced angioedema from beta-2 adrenergic receptor blockade at mucosal vascular beds; non-selective beta-blockers reduce epinephrine-mediated mast cell suppression, lowering the threshold for histamine-mediated angioedema; antihistamines will provide partial relief and the long-term management is switching to a beta-1 selective agent.
• C) This presentation is spironolactone-induced angioedema mediated by mineralocorticoid receptor blockade; aldosterone normally suppresses bradykinin B2 receptor expression at mucosal endothelium, and spironolactone's aldosterone receptor blockade upregulates B2 receptors above baseline, producing angioedema at normal bradykinin concentrations; antihistamines are ineffective but corticosteroids reduce B2 receptor gene transcription and will provide gradual relief.
• D) This presentation represents furosemide-induced hyponatremia causing low-oncotic-pressure facial edema that mimics angioedema; the absence of urticaria and pruritus distinguishes this from true angioedema; antihistamines and corticosteroids are irrelevant because the mechanism is fluid redistribution, and the correct management is reducing the furosemide dose and sodium restriction.
• E) This presentation is sacubitril-valsartan-associated bradykinin-mediated angioedema; LBQ657 inhibits neprilysin, impairing bradykinin degradation and elevating tissue bradykinin that activates B2 receptors at submucosal vascular endothelium; the mechanism involves no histamine release from mast cells, which is why there is no urticaria or pruritus and why antihistamines and corticosteroids — which target histamine signaling and inflammatory gene transcription respectively — have no pharmacological activity against bradykinin B2 receptor-driven vascular permeability.

11. [CASE 3 — QUESTION 3] Continuing with the same patient. The patient is brought to the emergency department. His airway is patent, voice is normal, and the angioedema is limited to the lips and tongue without progression. The emergency physician confirms the diagnosis of sacubitril-valsartan-associated bradykinin-mediated angioedema. Which of the following best represents the correct acute management of this event and the implications for his ongoing heart failure management?

• A) Sacubitril-valsartan should be continued at a reduced dose of 24/26 mg twice daily (the lowest approved dose) with close outpatient follow-up; dose reduction attenuates neprilysin inhibition sufficiently to prevent recurrent angioedema while preserving the majority of the drug's cardiovascular benefit in HFrEF; if angioedema recurs at the low dose, the drug can then be discontinued.
• B) Sacubitril-valsartan should be discontinued immediately; the patient should be monitored in the emergency department for airway compromise given that bradykinin-mediated angioedema can progress unpredictably; icatibant (B2 receptor antagonist) can be considered as a pharmacological intervention if angioedema progresses despite discontinuation; for ongoing heart failure management, valsartan alone (or an alternative ARB at guideline-recommended doses) can be substituted for sacubitril-valsartan, as ARBs do not raise bradykinin and do not carry this angioedema risk.
• C) Sacubitril-valsartan should be continued and the patient given high-dose methylprednisolone 1 mg/kg IV and diphenhydramine 50 mg IV; bradykinin-mediated angioedema responds to corticosteroids within 4 to 6 hours in most patients, and discontinuing sacubitril-valsartan in a patient with HFrEF and ejection fraction of 28% carries greater mortality risk than accepting a low-grade angioedema that can be pharmacologically controlled.
• D) Sacubitril-valsartan should be discontinued and the patient transitioned immediately back to enalapril 10 mg twice daily without a washout period; since the patient has already experienced sacubitril-valsartan angioedema, the bidirectional 36-hour washout requirement no longer applies because the angioedema itself has depleted bradykinin from mucosal tissue and the risk of synergistic accumulation during the reverse transition is negligible.
• E) Sacubitril-valsartan should be discontinued and the patient transitioned to valsartan monotherapy, but before any RAAS agent is started, a 7-day washout of sacubitril-valsartan is required to allow LBQ657 to clear completely; during this 7-day drug-free period, the patient's heart failure should be managed with increased furosemide dosing to compensate for the loss of RAAS blockade.

12. [CASE 3 — QUESTION 4] Continuing with the same patient. Two months later, the patient is stable on valsartan 160 mg twice daily with good blood pressure control. His cardiologist notes that a younger colleague has suggested rechallenge with sacubitril-valsartan at a lower starting dose given the significant mortality benefit data, arguing that the prior angioedema episode was mild and may have been coincidental. Which of the following best characterizes whether rechallenge with sacubitril-valsartan is appropriate and the pharmacological rationale for the decision?

• A) Rechallenge with sacubitril-valsartan is appropriate because the prior angioedema at the 49/51 mg dose does not predict angioedema at the lower 24/26 mg starting dose; neprilysin inhibition at lower doses raises bradykinin by a proportionally smaller amount, and patients who develop angioedema at higher doses frequently tolerate lower doses without recurrence after a 6-month drug-free interval.
• B) Rechallenge with sacubitril-valsartan is appropriate after confirming that the patient does not carry the ACE insertion/deletion polymorphism associated with increased bradykinin sensitivity; patients who are homozygous for the ACE deletion allele have a genetic predisposition to bradykinin-mediated angioedema that can be addressed by pre-treating with icatibant for the first 4 weeks of sacubitril-valsartan rechallenge.
• C) Rechallenge is appropriate because the fact that the patient tolerated enalapril for 4 years without angioedema before switching to sacubitril-valsartan confirms that his baseline ACE activity is sufficient to clear the modest bradykinin elevation produced by neprilysin inhibition alone; the prior angioedema episode therefore most likely represents a transient drug interaction rather than intrinsic bradykinin susceptibility.
• D) Rechallenge with sacubitril-valsartan is contraindicated; the patient has demonstrated bradykinin-mediated angioedema from neprilysin inhibition, establishing that his vascular endothelium is susceptible to bradykinin excess through this pathway; lower doses still produce neprilysin inhibition and still raise bradykinin, and there is no established safe dose of sacubitril-valsartan for patients who have experienced this adverse event; valsartan alone provides guideline-recommended RAAS blockade for HFrEF without neprilysin inhibition.
• E) Rechallenge is appropriate if conducted in a monitored inpatient setting with icatibant pre-loaded at the bedside; if no angioedema develops over a 48-hour monitored initiation period, sacubitril-valsartan can be continued as an outpatient; the monitored rechallenge strategy allows access to the mortality benefit of sacubitril-valsartan while managing the angioedema risk with on-site rescue therapy.

13. [CASE 4 — QUESTION 1] A 45-year-old woman with HAE type I has been on danazol 400 mg daily for 9 years with good attack control (fewer than one attack per year). At annual review her ALT is 4.2× and AST 3.1× the upper limit of normal. She has no jaundice, right upper quadrant pain, or symptoms of liver disease. Her abdominal ultrasound shows hepatomegaly with heterogeneous echogenicity but no focal lesions. She is otherwise in good health. Which of the following correctly identifies the cause of her hepatic findings and the appropriate pharmacological response?

• A) The transaminase elevation and hepatomegaly are caused by danazol-induced autoimmune hepatitis; danazol's androgenic metabolites act as haptens that bind to hepatocyte CYP enzymes, generating neoantigens that trigger T-cell-mediated hepatic inflammation; the correct treatment is to continue danazol at the same dose and add azathioprine 1 mg/kg daily as immunosuppression.
• B) The transaminase elevation is caused by danazol-induced hepatic steatosis from its lipid-altering effects; danazol's androgenic mechanism raises LDL and reduces HDL, and the resulting dyslipidemia causes hepatic fat accumulation that produces transaminase elevation; the correct management is to add a statin while continuing danazol and schedule a repeat liver biopsy in 12 months.
• C) The transaminase elevation and hepatomegaly represent dose-dependent androgenic hepatotoxicity from 9 years of danazol therapy — a well-documented adverse effect of long-term androgen use that can progress to peliosis hepatis or, rarely, hepatocellular carcinoma with prolonged exposure; danazol should be tapered and discontinued, and the patient transitioned to modern biologic HAE prophylaxis such as lanadelumab or subcutaneous pdC1-INH, which do not carry hepatotoxic risk.
• D) The hepatic findings reflect danazol-induced cholestatic jaundice from inhibition of hepatic bile acid transporters; danazol's androgenic structure binds to the BSEP transporter and blocks bile salt export, producing intrahepatic cholestasis; the ALT and AST elevation is secondary to cholestatic injury; ursodeoxycholic acid should be added to danazol therapy and dose reduction to 200 mg daily will normalize bile flow within 8 weeks.
• E) The transaminase elevation reflects CYP3A4 induction by danazol; after 9 years of therapy, danazol has maximally upregulated hepatic CYP3A4 activity, producing accelerated metabolism of multiple endogenous substrates including cortisol and estradiol; the hepatomegaly represents CYP3A4-induced hepatocyte hypertrophy, which is a benign adaptive response that requires no intervention beyond annual monitoring.

14. [CASE 4 — QUESTION 2] Continuing with the same patient. Danazol is tapered and the HAE specialist recommends initiating lanadelumab 300 mg subcutaneously every 2 weeks. The patient asks how lanadelumab differs from the C1-INH concentrate she received during two prior severe attacks, since both seem to target the same pathway. Which of the following most accurately explains the mechanistic difference between lanadelumab prophylaxis and C1-INH concentrate treatment?

• A) Lanadelumab and C1-INH concentrate have identical mechanisms because both ultimately prevent plasma kallikrein from generating bradykinin; lanadelumab simply has a longer half-life than IV C1-INH, which is why it can be used for prophylaxis at two-week intervals while C1-INH concentrate requires administration every 3 to 4 days; the distinction is entirely pharmacokinetic, not mechanistic.
• B) Lanadelumab is a fully human IgG1 monoclonal antibody that directly inhibits plasma kallikrein enzyme activity without restoring C1-INH levels or correcting the complement dysregulation of HAE; C1-INH concentrate replaces the deficient serpin itself, restoring physiological inhibitory control over both kallikrein and complement components C1r and C1s — normalizing C4 levels and the broader contact activation cascade — in addition to reducing bradykinin generation; both prevent bradykinin excess but at different system levels.
• C) The key mechanistic difference is route of action: lanadelumab acts extracellularly in the bloodstream to inhibit plasma kallikrein circulating in plasma, while C1-INH concentrate enters cells and inhibits tissue kallikrein isoforms inside synovial, epithelial, and glandular cells; this intracellular C1-INH activity is why concentrate replacement is needed for acute attacks while lanadelumab, which cannot enter cells, can only prevent attacks by suppressing the plasma kallikrein arm of bradykinin generation.
• D) Lanadelumab blocks plasma kallikrein through a covalent serpin-like mechanism, forming a permanent 1:1 complex with the enzyme that permanently removes it from circulation; C1-INH concentrate works through a reversible competitive inhibition of kallikrein that is overcome by high substrate (HMWK) concentrations during an attack, explaining why C1-INH concentrate is less effective than lanadelumab during established attacks where HMWK levels are high.
• E) Lanadelumab reduces HAE attack frequency by upregulating endogenous C1-INH synthesis through a compensatory feedback mechanism; by suppressing kallikrein activity, lanadelumab reduces the rate of C1-INH consumption during contact system activation, allowing endogenous C1-INH levels to rise toward normal over months of therapy; C1-INH concentrate replacement bypasses this endogenous upregulation pathway.

15. [CASE 4 — QUESTION 3] Continuing with the same patient. After 8 months on lanadelumab 300 mg every 2 weeks, the patient has been completely attack-free. She asks whether her dosing interval can be extended to monthly injections given the burden of twice-monthly visits. Her physician reviews the HELP trial data to counsel her. Which of the following correctly applies the clinical trial evidence to address her request?

• A) Extension of the lanadelumab dosing interval to once monthly (every 4 weeks) is not approved and cannot be offered; the HELP trial demonstrated that every-2-week dosing is strictly superior to every-4-week dosing in all patient subgroups, and any deviation from the every-2-week interval increases attack risk substantially even in patients with prolonged attack freedom.
• B) The HELP trial showed that lanadelumab reduces HAE attack rate by approximately 50% at the 300 mg every-2-week dose; patients who remain attack-free for 8 months represent a minority with exceptional drug sensitivity and may extend to every-4-week dosing, but this represents off-label use not supported by the prescribing information.
• C) Extension to every-4-week dosing can be offered immediately because 8 months of complete attack freedom exceeds the 6-month threshold; the HELP trial demonstrated that 44% of patients in the every-2-week arm achieved complete attack freedom, and subsequent pharmacokinetic modeling confirmed that trough concentrations at every-4-week dosing maintain full kallikrein inhibition in attack-free patients.
• D) Extension of the dosing interval from every 2 weeks to every 4 weeks is permitted by the prescribing information for patients who have been well-controlled and attack-free for at least 6 months on the every-2-week schedule; this patient qualifies for the extension; the HELP trial demonstrated that lanadelumab 300 mg every 2 weeks reduced HAE attack rate by approximately 87% versus placebo with 44% of patients achieving complete attack freedom — efficacy data that support the extension option in responsive patients.
• E) Extension to every-4-week dosing requires measurement of plasma lanadelumab trough concentrations at the 2-week dosing interval; only patients whose trough concentration exceeds 50 mcg/mL are eligible for interval extension, because this threshold corresponds to the minimum concentration associated with complete kallikrein inhibition in the HELP trial pharmacokinetic-pharmacodynamic analysis.

16. [CASE 4 — QUESTION 4] Continuing with the same patient. Now on lanadelumab every 4 weeks with continued attack freedom for 6 more months (14 months total), she is scheduled for elective laparoscopic cholecystectomy. Her surgeon asks the HAE specialist whether any pre-procedural pharmacological preparation is needed given that the patient is on effective biologic prophylaxis. Which of the following correctly identifies the appropriate perioperative pharmacological management?

• A) Short-term prophylaxis with intravenous plasma-derived C1-INH concentrate administered 1 to 6 hours before surgery is still recommended despite effective lanadelumab prophylaxis; the intensity of contact system activation from surgical trauma can transiently exceed steady-state kallikrein inhibition, and HAE guidelines recommend pre-procedural STP for all HAE patients undergoing major surgical procedures regardless of their current prophylactic regimen.
• B) No pre-procedural pharmacological preparation is needed because the patient has been attack-free for 14 months on lanadelumab; attack freedom for more than 12 months on a biologic agent is the threshold above which HAE guidelines waive the short-term prophylaxis requirement for elective surgery, based on data showing that prolonged attack freedom correlates with sufficiently suppressed kallikrein activity to withstand surgical contact system activation.
• C) Pre-procedural preparation should consist of administering an additional lanadelumab 300 mg dose 48 hours before surgery rather than C1-INH concentrate; the additional biologic dose raises plasma kallikrein inhibitor concentrations above the steady-state level and provides additional margin against the surgical activation stimulus without introducing a separate pharmacological class.
• D) Pre-procedural pharmacological preparation should include stopping lanadelumab 2 weeks before surgery to allow complete drug washout; residual lanadelumab at the time of surgery could interfere with the normal contact system response to surgical trauma that is needed for physiological hemostasis at the operative site, and the lanadelumab-free surgical period should be covered with on-demand icatibant at the bedside.
• E) The patient should receive fresh frozen plasma 1 unit intravenously in the preoperative holding area as short-term prophylaxis; FFP is preferred over C1-INH concentrate for perioperative HAE prophylaxis in patients on lanadelumab because lanadelumab inhibits kallikrein-mediated HMWK cleavage, and FFP's HMWK content provides additional substrate to maintain normal bradykinin signaling that the patient's kallikrein inhibition might otherwise suppress to sub-physiological levels.

17. [CASE 5 — QUESTION 1] A 31-year-old woman presents to the allergy clinic with a 4-year history of recurrent episodes of facial, abdominal, and hand swelling. Her attacks began when she started a combined oral contraceptive containing ethinylestradiol and worsen premenstrually and during high-stress periods. She has had three emergency department visits during which she received antihistamines, corticosteroids, and epinephrine with no improvement in attack duration or severity. C1-INH level is 0.32 g/L (normal 0.21 to 0.39 g/L), C1-INH functional activity is 98% (normal), and C4 is 0.25 g/L (normal). She has a family history of similar angioedema episodes in her mother. Which of the following correctly identifies the most likely diagnosis, the molecular basis for the normal complement studies, and the reason the attacks are estrogen-sensitive?

• A) This patient has acquired C1-INH deficiency (AAE type I) caused by autoantibodies consuming C1-INH; the normal measured C1-INH level reflects compensatory hepatic overproduction that masks consumption; estrogen sensitivity occurs because estrogen upregulates anti-C1-INH autoantibody production through an estrogen-response element in the promoter of the pathogenic immunoglobulin gene.
• B) This patient has HAE type II, in which the C1-INH protein is present at normal or elevated concentrations but is dysfunctional; the normal C1-INH functional activity result is a false negative caused by the assay's inability to detect the specific reactive-center-loop mutation present in this patient's variant C1-INH; estrogen sensitivity reflects a direct conformational effect of estradiol on the mutant reactive center loop that further impairs its serpin activity.
• C) This patient has HAE type III, most likely caused by a gain-of-function mutation in factor XII that makes it abnormally susceptible to estrogen-induced activation; standard complement screening is normal because the defect is not in C1-INH — which is structurally and functionally intact — but in factor XII itself, which does not affect C1-INH levels or C4 consumption between attacks; ethinylestradiol worsens attacks by inducing conformational changes in factor XII that promote spontaneous activation of the mutant protein.
• D) This patient has idiopathic histaminergic angioedema with estrogen-dependent mast cell priming; estrogen upregulates the FcεRI receptor on skin and mucosal mast cells, increasing their sensitivity to IgE-mediated degranulation by unidentified environmental allergens; the normal complement studies and antihistamine failure are both attributable to estrogen-induced receptor upregulation that exceeds the H1 blocking capacity of standard antihistamine doses.
• E) This patient has hereditary alpha-tryptasemia — a condition in which elevated baseline serum tryptase from mast cell overabundance causes recurrent angioedema; estrogen sensitivity results from estrogen-dependent upregulation of KIT (c-Kit) receptor expression on mast cells, increasing their proliferative response to stem cell factor and amplifying the mast cell burden during high-estrogen states; complement studies are normal because this condition does not involve the kallikrein-kinin or complement systems.

18. [CASE 5 — QUESTION 2] Continuing with the same patient. The allergist confirms the diagnosis of HAE type III and explains that standard HAE acute treatments can be used. The patient is confused because she understood that HAE type III involves a different molecular defect than types I and II, and asks why the same drugs would work. Which of the following best explains why icatibant, ecallantide, and C1-INH concentrate are all pharmacologically appropriate acute treatments for HAE type III attacks despite the different upstream molecular defect?

• A) Icatibant, ecallantide, and C1-INH concentrate are appropriate for type III because all three agents also directly inhibit the mutant factor XII protein; by binding to the estrogen-responsive activation site on the type III factor XII mutant, all three drugs prevent the initiating step of kallikrein generation regardless of the kallikrein-kinin cascade entry point.
• B) The same agents work in type III because HAE type III actually involves C1-INH deficiency at the tissue level (not in plasma); tissue C1-INH concentrations are reduced by the factor XII gain-of-function mutation through a local feedback mechanism that the plasma C1-INH assay cannot detect; C1-INH concentrate replenishes the tissue deficit, while ecallantide and icatibant address the downstream bradykinin excess.
• C) These agents are appropriate because HAE type III attacks are caused by a different mediator — des-Arg9-bradykinin acting at B1 receptors — which is the same mediator that causes types I and II attacks; icatibant's B2 receptor antagonism cross-reacts with B1 receptors at the high doses used in acute treatment, providing efficacy across both receptor subtypes regardless of which subtype is primarily activated.
• D) Despite the different upstream molecular defect — factor XII gain-of-function in type III versus C1-INH deficiency in types I and II — all three HAE subtypes produce the same final mediator: bradykinin acting at B2 receptors on vascular endothelium to drive increased permeability and tissue edema; icatibant blocks the B2 receptor (the effector), ecallantide blocks plasma kallikrein (the bradykinin-generating enzyme), and C1-INH concentrate inhibits kallikrein through serpin trapping — all three interrupt the cascade at a point that is equally effective regardless of whether excess kallikrein was generated by C1-INH deficiency or by a constitutively overactive factor XII mutant.
• E) These agents are specifically approved for HAE type III by the FDA, and their efficacy is established by phase III randomized controlled trials that enrolled type III patients; the approval for type III use required demonstration of equivalent pharmacological activity against the type III factor XII mutant kallikrein isoform that differs structurally from the kallikrein generated in C1-INH-deficient HAE types I and II.

19. [CASE 5 — QUESTION 3] Continuing with the same patient. The allergist recommends stopping her combined oral contraceptive. The patient asks for the precise pharmacological explanation of why her OCP is worsening her HAE type III attacks, and whether any form of hormonal contraception is safe. Which of the following correctly explains the mechanism by which ethinylestradiol worsens HAE type III and identifies an appropriate contraceptive alternative?

• A) Ethinylestradiol worsens HAE type III through a dual hepatic mechanism: it upregulates HMWK gene expression through estrogen response elements in the HMWK gene promoter — increasing plasma concentrations of the bradykinin precursor that kallikrein cleaves — while simultaneously downregulating hepatic C1-INH synthesis, reducing the already-limited inhibitory control over the constitutively overactive factor XII mutant; progestin-only contraceptives (progestin-only pills, etonogestrel implant, or levonorgestrel-releasing IUD) do not substantially alter HMWK or C1-INH gene expression and are generally well-tolerated in HAE patients.
• B) Ethinylestradiol worsens HAE type III by directly binding to the gain-of-function factor XII mutant protein and inducing the conformational change that activates it; without estrogen binding, the mutant factor XII remains in its zymogen form and contact system activation does not occur; stopping ethinylestradiol eliminates this direct pharmacological activation of the mutant protein; no hormonal contraception is safe in type III because all steroid hormones share the structural scaffold that binds the mutant factor XII activation site.
• C) Ethinylestradiol worsens attacks because it upregulates the bradykinin B2 receptor at vascular endothelial surfaces through an estrogen response element in the B2 receptor gene promoter; the increased receptor density amplifies the permeability response to any given bradykinin concentration, lowering the effective attack threshold; levonorgestrel-containing combined OCPs are safe alternatives because levonorgestrel's androgenic properties counteract estrogen's B2 receptor upregulation.
• D) Ethinylestradiol worsens HAE type III by competitively inhibiting C1-INH binding to plasma kallikrein through a shared binding site on the kallikrein active site; at therapeutic plasma concentrations of ethinylestradiol, the proportion of kallikrein with C1-INH bound falls to less than 10% of normal, functionally reproducing the state of C1-INH deficiency seen in HAE types I and II; stopping ethinylestradiol restores normal C1-INH-kallikrein binding, normalizing contact system control.
• E) Ethinylestradiol worsens HAE type III by suppressing the pituitary-ovarian axis and eliminating the progesterone surge of the luteal phase; endogenous progesterone normally upregulates C1-INH synthesis and suppresses factor XII expression, so OCP-induced progesterone suppression removes this protective hormonal influence; the appropriate contraceptive alternative is a progesterone-releasing IUD, which restores local uterine progesterone without systemic pituitary suppression.

20. [CASE 5 — QUESTION 4] Continuing with the same patient. The patient has switched to a progestin-only pill and stopped ethinylestradiol. Her attack frequency has decreased significantly but she still has one to two attacks per month. The allergist and HAE specialist discuss long-term prophylaxis. Which of the following correctly characterizes the prophylactic options available for HAE type III and the additional non-pharmacological management that is essential in this patient?

• A) Long-term prophylaxis for HAE type III must use danazol as first-line because type III involves abnormal factor XII activation rather than C1-INH deficiency; danazol's androgenic upregulation of C1-INH synthesis addresses the specific inhibitory gap created by the factor XII gain-of-function mutation that targeted biologic agents cannot overcome in type III.
• B) Lanadelumab is contraindicated in HAE type III because its mechanism of plasma kallikrein inhibition presupposes that kallikrein activation is driven by the normal contact system cascade; in type III, the factor XII gain-of-function mutant generates kallikrein through a fundamentally different molecular pathway that bypasses the kallikrein active site that lanadelumab binds, rendering the drug pharmacologically inactive.
• C) Long-term prophylaxis for type III should use intravenous Cinryze exclusively because subcutaneous agents (lanadelumab, HAEGARDA) have not been tested in factor XII HAE type III; the intravenous route ensures complete bioavailability of C1-INH without the variable absorption that could leave subcutaneous dosing insufficient against the type III factor XII-driven kallikrein storm.
• D) Long-term prophylaxis is not indicated for HAE type III because the underlying genetic defect (gain-of-function factor XII mutation) produces attacks exclusively through estrogen-dependent pathways; eliminating the ethinylestradiol trigger is curative in all type III patients, and biologic prophylaxis should be reserved for the rare patient who continues to have attacks after complete estrogen avoidance.
• E) Lanadelumab, subcutaneous pdC1-INH (HAEGARDA), and intravenous pdC1-INH (Cinryze) are all appropriate prophylactic options for HAE type III based on the pharmacological principle that reducing plasma kallikrein activity or restoring C1-INH inhibitory control limits bradykinin generation regardless of the upstream trigger; estrogen avoidance — specifically avoiding ethinylestradiol-containing contraceptives, hormone replacement therapy, and other exogenous estrogen sources — is an essential non-pharmacological component of attack prevention that should be pursued alongside pharmacological prophylaxis.

21. [CASE 6 — QUESTION 1] A 59-year-old man with type 2 diabetes is admitted to the medical ICU with gram-negative septic shock secondary to E. coli urosepsis. Despite 3 liters of crystalloid resuscitation, norepinephrine at 0.35 mcg/kg/min, and vasopressin at 0.03 units/min, his mean arterial pressure is 54 mmHg. Blood cultures are positive for E. coli. His lactate is 5.8 mmol/L. He is intubated and mechanically ventilated. The intensivist asks whether the contact activation cascade is contributing to his refractory vasodilatory hypotension through mechanisms beyond the known iNOS-derived nitric oxide pathway. Which of the following correctly identifies how gram-negative LPS activates the kallikrein-kinin system and the vasodilatory mechanism it produces that is not addressed by the current vasopressor regimen?

• A) E. coli LPS directly activates the bradykinin B2 receptor through its lipid A moiety, which shares structural homology with the bradykinin nonapeptide sequence; this structural mimicry allows LPS to act as a partial B2 receptor agonist at the high LPS concentrations achieved in gram-negative bacteremia, producing vasodilation through the same Gq-signaling pathway as bradykinin but without requiring kallikrein-mediated bradykinin generation.
• B) E. coli LPS activates complement C3 through the alternative pathway, generating C3a that competitively antagonizes norepinephrine at alpha-1 adrenergic receptors; the resulting reduction in norepinephrine-mediated vasoconstriction accounts for the refractory hypotension, and complement inhibition with eculizumab (a C5 inhibitor) is the pharmacological approach most likely to restore vasopressor responsiveness in this patient.
• C) E. coli LPS activates mast cells through TLR4 signaling, triggering simultaneous histamine and bradykinin co-release; histamine activates H1 receptors on vascular smooth muscle cells producing vasodilation, and bradykinin activates B2 receptors on endothelial cells producing vascular leak; norepinephrine effectively counters histamine-mediated smooth muscle vasodilation but cannot overcome the endothelial permeability component, which requires H2 receptor blockade to control.
• D) E. coli LPS activates the coagulation cascade exclusively through tissue factor expression on activated monocytes and endothelial cells; the resulting thrombin generation degrades bradykinin through thrombin's intrinsic carboxypeptidase activity, paradoxically reducing bradykinin concentrations below basal levels during septic shock; the refractory hypotension is therefore driven entirely by nitric oxide and prostaglandins rather than by bradykinin excess.
• E) E. coli lipopolysaccharide (LPS) and the neutrophil extracellular traps (NETs) released by activated neutrophils provide negatively charged surfaces that activate factor XII, initiating the contact system cascade and driving plasma kallikrein generation; active plasma kallikrein cleaves HMWK to produce bradykinin, which activates B2 receptors on vascular endothelium producing vasodilation and increased microvascular permeability; this mechanism is independent of the iNOS/nitric oxide pathway and operates through a Gq-coupled signaling pathway entirely distinct from the alpha-1 adrenergic and V1a vasopressin receptors targeted by the current vasopressor regimen.

22. [CASE 6 — QUESTION 2] Continuing with the same patient. Eighteen hours into his ICU admission, despite escalating norepinephrine to 0.6 mcg/kg/min and adding hydrocortisone for possible relative adrenal insufficiency, the patient's MAP remains 56 mmHg. His cytokine levels are markedly elevated (IL-6, TNF-alpha, IL-1 beta). The intensivist notes that the B2 receptor-mediated bradykinin vasodilation should be self-limiting because B2 receptors desensitize with sustained agonist exposure. However, a senior colleague suggests the B1 receptor may now be contributing to the sustained hypotension. Which of the following correctly explains the pharmacological basis for B1 receptor involvement at this stage of septic shock?

• A) The B1 receptor contributes to sustained hypotension because it is constitutively expressed at high density on vascular smooth muscle from baseline, providing a persistent vasodilatory signal that the B2 receptor — expressed only on endothelial cells — cannot generate; after 18 hours of sepsis, endothelial B2 receptor desensitization has reduced endothelial vasodilatory signaling to negligible levels, leaving B1-mediated smooth muscle vasodilation as the dominant bradykinin-driven mechanism.
• B) The cytokines generated by the septic inflammatory response — particularly TNF-alpha and IL-1 beta — dramatically upregulate B1 receptor expression at vascular beds that had low baseline B1 receptor density; unlike the B2 receptor, the B1 receptor does not undergo desensitization through receptor internalization with sustained agonist stimulation — sustained signaling by des-Arg9-bradykinin (the primary B1 receptor agonist, formed from bradykinin by carboxypeptidase N) through this inducible, non-desensitizing receptor provides a persistent vasodilatory signal that amplifies and extends the acute B2-mediated phase.
• C) The B1 receptor contributes by amplifying iNOS-derived nitric oxide; cytokine-activated B1 receptors on endothelial cells directly transactivate the iNOS gene promoter through a Gi-coupled cAMP signaling pathway that is distinct from the classic NF-kB pathway used by TNF-alpha; this B1-iNOS axis is additive to the cytokine-driven iNOS upregulation already occurring, explaining why iNOS inhibitors alone do not fully restore vasomotor tone in septic shock.
• D) The B1 receptor becomes relevant at 18 hours because bradykinin has been degraded by ACE and neprilysin to des-Arg9-bradykinin, and des-Arg9-bradykinin is approximately 10-fold more potent than bradykinin itself at the B2 receptor; the apparent "B1 contribution" actually represents des-Arg9-bradykinin acting at the B2 receptor with enhanced potency — the B1 receptor itself is not pharmacologically significant in gram-negative sepsis because it is expressed only on non-vascular neural tissue.
• E) The B1 receptor desensitizes even more rapidly than the B2 receptor in the setting of elevated TNF-alpha; the sustained hypotension is therefore not explained by ongoing bradykinin receptor signaling but by TNF-alpha-mediated downregulation of the Gq signaling pathway shared by both B1 and B2 receptors, which renders both receptors constitutively active through ligand-independent signaling that norepinephrine cannot reverse.

23. [CASE 6 — QUESTION 3] Continuing with the same patient. The intensivist asks a clinical pharmacologist consultant whether bradykinin-targeted agents such as icatibant or garadacimab have been investigated for septic shock, and why none are currently approved for this indication. Which of the following most accurately summarizes the investigational landscape and the pharmacological challenges that have limited clinical translation of bradykinin-targeted therapy in sepsis?

• A) Icatibant and garadacimab have not been investigated in septic shock because their mechanisms are irrelevant to gram-negative sepsis; E. coli LPS activates hypotension exclusively through TLR4-NF-kB-iNOS signaling, not through the kallikrein-kinin contact system; bradykinin receptor antagonists and kallikrein inhibitors have no theoretical pharmacological basis in gram-negative sepsis.
• B) Bradykinin-targeted agents have been tested extensively in large phase III trials of septic shock and have consistently shown vasopressor-sparing effects in gram-negative sepsis; however, none are approved because the FDA requires demonstration of 28-day mortality reduction as the primary endpoint, and while hemodynamic improvement is reproducible, survival benefit has not been statistically significant in the trials conducted to date.
• C) Garadacimab has received FDA Breakthrough Therapy Designation for vasopressor-refractory septic shock based on phase II data showing 40% reduction in vasopressor requirements at 24 hours compared to placebo; the designation requires completion of a confirmatory phase III trial before approval, which is currently enrolling in 30 ICUs across North America.
• D) Pilot studies of icatibant and other B2 receptor antagonists in septic shock models demonstrated transient hemodynamic benefit, but clinical translation has been hampered by icatibant's short plasma half-life of 1 to 2 hours (requiring continuous infusion or frequent repeat dosing) and the pharmacological reality that bradykinin is only one of multiple simultaneously active vasodilatory mediators in sepsis — including iNOS-derived nitric oxide, prostacyclin, and complement-derived anaphylatoxins — meaning that B2 blockade alone does not fully restore vasomotor tone.
• E) Bradykinin-targeted therapy in sepsis has been abandoned after a definitive phase III trial (the KININ-SHOCK trial, 1,200 patients) showed that icatibant worsened 28-day mortality in gram-negative septic shock by impairing the protective bradykinin-mediated vasodilation that is required for adequate microvascular perfusion of the renal cortex; the trial results established bradykinin B2 receptor signaling as essential for renal protection in sepsis.

24. [CASE 6 — QUESTION 4] Continuing with the same patient. His condition stabilizes over 72 hours and he is eventually extubated. During rounds, a medical student asks the intensivist about the "bradykinin hypothesis" of COVID-19 ARDS, having read about it in a pharmacology review, and asks how it differs mechanistically from the kallikrein-kinin contribution to septic hypotension just discussed. Which of the following correctly distinguishes the bradykinin pharmacology of COVID-19 ARDS from that of gram-negative septic shock?

• A) The COVID-19 and gram-negative septic shock bradykinin mechanisms are pharmacologically identical; both involve factor XII activation leading to plasma kallikrein generation and B2 receptor-mediated vascular permeability; the only difference is the initial trigger (SARS-CoV-2 spike protein vs. LPS), and both could theoretically be treated with icatibant as a B2 receptor antagonist.
• B) In COVID-19, bradykinin accumulation occurs in the systemic circulation and produces the systemic hypotension of COVID-19 ARDS through the same B2-mediated mechanism as gram-negative sepsis; in gram-negative septic shock, bradykinin is generated exclusively at local tissue sites and does not enter systemic circulation; the difference is the compartmentalization of bradykinin generation rather than the receptor involved.
• C) In COVID-19, SARS-CoV-2 downregulates ACE2 at the pulmonary endothelium; ACE2 normally degrades des-Arg9-bradykinin (the B1 receptor agonist formed from bradykinin by carboxypeptidase N), so ACE2 depletion specifically allows des-Arg9-bradykinin to accumulate at the lung endothelium — and the concurrent cytokine storm upregulates B1 receptor expression — producing sustained B1-mediated pulmonary vascular permeability; this is distinct from gram-negative septic shock, where the primary acute mechanism is B2 receptor activation by kallikrein-generated bradykinin with B1 contributing later through cytokine-driven upregulation.
• D) In COVID-19, the bradykinin hypothesis proposes that SARS-CoV-2 directly inhibits plasma kallikrein through spike protein binding, paradoxically reducing bradykinin generation below normal levels; the resulting bradykinin deficiency impairs B2 receptor-mediated endothelial nitric oxide production, causing pulmonary hypertension rather than vasodilation; this is the opposite of the vasodilatory mechanism in gram-negative septic shock.
• E) The COVID-19 bradykinin hypothesis is now considered definitively refuted by randomized controlled trials of icatibant in hospitalized COVID-19 patients showing no reduction in oxygen requirements, ICU admission rates, or mortality; the septic shock bradykinin mechanism remains pharmacologically supported, distinguishing the two clinical contexts solely by the strength of clinical trial evidence rather than by mechanistic differences.

25. [CASE 7 — QUESTION 1] A 62-year-old man with severe bilateral knee osteoarthritis presents to rheumatology with persistent joint pain rated 7/10 despite maximum-dose naproxen 500 mg twice daily and acetaminophen 1 g four times daily. He has had three intra-articular corticosteroid injections in the past year with progressively shorter duration of relief. Synovial fluid analysis shows inflammatory cells with elevated IL-1 beta and TNF-alpha concentrations. His rheumatologist explains that bradykinin-mediated nociception may be contributing to his refractory pain through a receptor that is particularly active in chronically inflamed joints. Which of the following most accurately identifies the specific bradykinin receptor responsible for sustained joint pain in this clinical context and explains why it is not addressed by NSAIDs?

• A) The bradykinin B2 receptor is responsible for sustained joint pain in chronic OA; it is constitutively upregulated in inflamed synovium through a prostaglandin-dependent mechanism, explaining why NSAIDs provide partial but incomplete pain relief — by reducing prostaglandins, NSAIDs lower B2 receptor density but cannot eliminate B2-mediated sensitization because residual bradykinin at prostaglandin-independent B2 receptors continues to produce nociceptor activation.
• B) The bradykinin B1 receptor is responsible for sustained chronic joint pain in this patient; pro-inflammatory cytokines present in his synovial fluid — particularly IL-1 beta and TNF-alpha — upregulate B1 receptor expression on peripheral nociceptive neurons and synovial cells through NF-kB-mediated transcriptional activation; unlike the B2 receptor (which undergoes receptor internalization and desensitization with sustained agonist exposure), the B1 receptor does not desensitize — producing a persistent, non-diminishing nociceptive signal from des-Arg9-bradykinin that NSAIDs cannot address because they target prostaglandin synthesis rather than bradykinin receptor signaling.
• C) The bradykinin B1 receptor is responsible, but only indirectly: IL-1 beta and TNF-alpha in the synovial fluid upregulate COX-2, which generates prostaglandin E2 that transactivates the B1 receptor through a shared cyclic AMP signaling intermediate; NSAIDs fail to relieve the B1 component because prostaglandin E2 is required for B1 receptor transactivation, and in this patient the COX-2 activity has saturated all available B1 receptors before naproxen can competitively suppress prostaglandin production.
• D) The bradykinin B2 receptor mediates sustained joint pain in chronic OA through a non-desensitizing mechanism that emerges after prolonged bradykinin exposure; chronic B2 receptor activation in inflamed synovium drives receptor phosphorylation by GRK2 that paradoxically converts the B2 receptor from a desensitizing to a constitutively active conformation, maintaining nociceptive signaling even when bradykinin concentrations fall below the normal activation threshold; NSAIDs cannot reverse this receptor phosphorylation.
• E) Neither B1 nor B2 receptors are responsible for the refractory pain; bradykinin contributes to acute pain in OA through transient B2 receptor activation during acute inflammatory flares, but chronic OA pain after the acute phase is mediated entirely by substance P acting at neurokinin-1 receptors on dorsal horn neurons; NSAIDs fail because substance P signaling is prostaglandin-independent.

26. [CASE 7 — QUESTION 2] Continuing with the same patient. The rheumatologist explains that while the B1 receptor mediates his sustained chronic pain, the bradykinin B2 receptor also contributes to acute pain flares in his OA joints — and that understanding B2 receptor signaling explains why intra-articular corticosteroid injections provide only temporary relief rather than sustained pain control. Which of the following correctly describes the B2 receptor's role in acute OA nociception and the pharmacological reason corticosteroid injections do not provide durable B2-mediated pain relief?

• A) The B2 receptor mediates acute OA pain by activating adenylyl cyclase through Gs coupling, raising intracellular cAMP that activates protein kinase A; PKA then phosphorylates voltage-gated sodium channels on nociceptive neurons, lowering their activation threshold; corticosteroid injections fail to provide durable relief because they upregulate phosphodiesterase activity, which breaks down the cAMP signal and paradoxically sensitizes nociceptors to subsequent bradykinin stimulation.
• B) The B2 receptor mediates acute OA pain by directly opening mechanosensitive ion channels on chondrocytes; bradykinin B2 receptor activation in cartilage triggers calcium influx that drives chondrocyte apoptosis, reducing the cartilage buffer between bone surfaces; corticosteroid injections provide temporary relief by inhibiting B2 receptor gene transcription, but the chondrocyte apoptosis continues because corticosteroids cannot reverse established cell death.
• C) The B2 receptor is not expressed in joint tissue and does not contribute to OA pain; bradykinin-mediated acute OA pain flares are entirely mediated by B1 receptors that are transiently overactivated during mechanical loading events; corticosteroids provide temporary relief in acute flares by reducing the cytokine-driven B1 receptor upregulation that is re-established within weeks of each injection as local inflammation recovers.
• D) The B2 receptor is constitutively expressed on peripheral nociceptive neurons in the joint; bradykinin (generated acutely during synovial inflammation) activates B2 receptors via Gq/phospholipase C signaling, producing downstream PKC activation that phosphorylates TRPV1 and TRPA1 ion channels — lowering their thermal and chemical activation thresholds and amplifying nociceptor responses to mechanical and inflammatory stimuli; corticosteroid injections provide temporary relief by suppressing synovial bradykinin generation (through reduced arachidonic acid release and contact system activation), but as local inflammation recovers over weeks, bradykinin generation resumes and acute B2-mediated sensitization recurs.
• E) The B2 receptor contributes to acute OA pain by competitively displacing endogenous enkephalins from mu-opioid receptors on nociceptive neurons, removing endogenous analgesia; corticosteroid injections restore enkephalin binding by suppressing B2 receptor expression through glucocorticoid response elements in the B2 receptor gene promoter, but as corticosteroid levels fall after the injection, B2 receptor expression returns to baseline within 4 to 6 weeks, restoring competitive enkephalin displacement and recurring pain.

27. [CASE 7 — QUESTION 3] Continuing with the same patient. During the clinic visit, the patient mentions that his daughter has HAE and has read about a new oral medication called donidalorsen that is in development. He asks how it works and how it compares to icatibant, which his daughter currently uses. The rheumatologist defers to an HAE consultant colleague who explains the pharmacological comparison. Which of the following correctly distinguishes donidalorsen from icatibant in terms of mechanism and the pharmacological significance of donidalorsen's oral route?

• A) Donidalorsen and icatibant have identical mechanisms — both are competitive antagonists at the bradykinin B2 receptor — but donidalorsen achieves oral bioavailability through a glycosylation modification that protects the B2 antagonist pharmacophore from gastrointestinal peptidase degradation; icatibant requires subcutaneous injection because its non-natural amino acid substitutions, while providing plasma protease resistance, are cleaved by intestinal brush-border peptidases before absorption.
• B) Donidalorsen inhibits the bradykinin B1 receptor rather than the B2 receptor; by blocking B1 specifically, donidalorsen prevents the sustained, non-desensitizing nociceptive and vasodilatory signaling of des-Arg9-bradykinin without interfering with the acute B2 receptor-mediated physiological effects of bradykinin (vasodilation, natriuresis, cardioprotection); icatibant blocks B2 receptors and has no B1 activity, making the two agents pharmacologically complementary rather than competitive.
• C) Donidalorsen is an oral small-molecule inhibitor of plasma kallikrein — the enzyme that cleaves HMWK to generate bradykinin — acting upstream of bradykinin formation; icatibant is a subcutaneous synthetic decapeptide that acts downstream as a competitive B2 receptor antagonist, blocking bradykinin already formed from activating its effector receptor; donidalorsen's oral route is pharmacologically significant because all currently approved acute HAE treatments require subcutaneous or intravenous injection, and oral dosing at attack onset would substantially expand treatment access for patients who are averse to self-injection or face barriers to injectable medications.
• D) Donidalorsen and icatibant are both inhibitors of plasma kallikrein; donidalorsen is an oral small-molecule kallikrein inhibitor and icatibant is a subcutaneous peptide kallikrein inhibitor; the key distinction is that icatibant's non-natural amino acid structure allows it to inhibit kallikrein in both plasma and tissue compartments, while donidalorsen's small-molecule structure restricts it to plasma kallikrein inhibition only, making donidalorsen less effective for laryngeal attacks where tissue kallikrein predominates.
• E) Donidalorsen inhibits factor XIIa rather than plasma kallikrein, placing it two steps upstream of icatibant in the contact activation cascade; by preventing kallikrein activation rather than blocking kallikrein itself, donidalorsen produces more complete suppression of bradykinin generation — including from alternative kallikrein activation pathways that are not factor XIIa-dependent; its oral route reflects its small-molecule structure, which was optimized for gastrointestinal absorption during lead compound development.

28. [CASE 7 — QUESTION 4] Continuing with the same patient. The HAE consultant continues to counsel the patient about his daughter's treatment options and the expanding pipeline. She mentions that garadacimab is another investigational agent targeting HAE prophylaxis at a different point in the contact cascade than either donidalorsen or lanadelumab. The patient asks the consultant to explain how the three pipeline agents — garadacimab, donidalorsen, and lanadelumab — differ in where they act in the contact activation cascade, and what pharmacological advantage upstream intervention provides. Which of the following correctly maps the cascade positions of all three agents and identifies the theoretical advantage of garadacimab's upstream position?

• A) Garadacimab is an anti-factor XIIa monoclonal antibody that blocks the contact cascade at its triggering step — factor XII activation — one step upstream of plasma kallikrein; lanadelumab and donidalorsen both target plasma kallikrein (lanadelumab as a monoclonal antibody for prophylaxis, donidalorsen as an oral small molecule for acute attack treatment); by acting at factor XIIa, garadacimab theoretically blocks not only bradykinin generation but also the contact system's contribution to coagulation through the intrinsic pathway — a broader upstream suppression of contact system activation that kallikrein-targeting agents cannot achieve.
• B) Garadacimab targets plasma kallikrein (same as lanadelumab) but at a different epitope — the exosite rather than the active site; donidalorsen targets factor XIIa (one step upstream of kallikrein); icatibant blocks the B2 receptor (one step downstream of bradykinin generation); the three agents form a pharmacologically graded cascade sequence from upstream to downstream, and garadacimab's exosite mechanism is theoretically superior because it does not compete with HMWK for kallikrein binding.
• C) Donidalorsen targets factor XIIa (the contact cascade trigger), lanadelumab targets HMWK (the bradykinin precursor), and garadacimab targets plasma kallikrein; the three agents span the contact cascade from trigger (factor XIIa) to substrate (HMWK) to enzyme (kallikrein), providing pharmacologically complementary coverage of every step before bradykinin generation; their combined use for refractory HAE represents the most complete upstream suppression strategy available.
• D) All three agents — garadacimab, donidalorsen, and lanadelumab — target the same molecular site on plasma kallikrein but through different binding modes; garadacimab is a monoclonal antibody using CDR-mediated active site occlusion, lanadelumab is a monoclonal antibody using allosteric active site modulation, and donidalorsen is a small molecule using direct competitive active site inhibition; the term "upstream" for garadacimab refers to its position in the therapeutic development timeline rather than its position in the contact cascade.
• E) Garadacimab targets the bradykinin B1 receptor (providing prophylactic B1 blockade), lanadelumab targets plasma kallikrein (reducing bradykinin generation for prophylaxis), and donidalorsen targets the bradykinin B2 receptor (providing acute attack relief); the three agents together cover the full spectrum from upstream biosynthetic inhibition (lanadelumab) through B1-mediated sustained sensitization blockade (garadacimab) to downstream B2 receptor effector blockade (donidalorsen) for both prophylaxis and acute treatment.